



02-09-04

Docket 17610 (BOT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: HOWARD I. KATZ, et al) Examiner:
Serial Number: 10/685,986)
Filed: October 14, 2003) Art Unit:
For: BOTULINUM TOXIN DENTAL)
THERAPIES AND PROCEDURES) Irvine, California

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Applicant's provide with regard to the patent application entitled BOTULINUM TOXIN DENTAL THERAPIES AND PROCEDURES, filed herewith one copy of a documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: February 5, 2004


Stephen Donovan
Registration Number 33,433

Please direct all inquiries and correspondence to:


Stephen Donovan
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: 714.246.4026
Fax: 714.246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed herein are being deposited with the United States Postal Service on this date February 5, 2004, in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EV193717258US addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Bartholomew

Name of person mailing paper


Signature of person mailing paper

Date: February 5, 2004



LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17610 (BOT)	SERIAL NO.: 10/685,986
APPLICANT: KATZ et al.	TITLE: BOTULINUM TOXIN DENTAL THERAPIES AND PROCEDURES
FILING DATE: October 14, 2003	GROUP:

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	10/194805		Donovan			7/11/02
	AB	5,298,019	3/29/1994	Borodic, Gary E.			
	AC	5,437,291	8/1/1995	Pasricha et al.			
	AD	5,670,484	9/23/1997	Binder, William J.			
	AE	5,714,468	2/3/1998	Binder, William J.			
	AF	5,766,605	6/16/1998	Sanders et al.			
	AG	5,989,545	11/23/1999	Foster et al.			
	AH	6,063,768	5/16/2000	First, Eric R.			
	AI	6,139,845	10/31/2000	Donovan			
	AJ	6,265,379	7/24/2001	Donovan			
	AK	6,299,893	10/9/2001	Schwartz et al.			
	AL	6,306,423	10/23/2001	Donovan et al.			
	AM	6,312,708	11/6/2001	Donovan			
	AN	6,358,917	3/19/2002	Carruthers et al.			
	AO	6,358,926	3/19/2002	Donovan			
	AP	6,423,319	7/23/2002	Brooks et al.			
	AQ	6,458,365	10/1/2002	Aoki et al.			
	AR	6,464,986	10/15/2002	Aoki et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						
	BK						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CA	Anderson et al.; Presence of matrix associated vesicles in tooth pulp that are immunoreactive for syntaxin and L-type calcium channels; Univ of Washington, Seattle; Anesthesiol; Pharmacol; Abstract (Society for Neuroscience)
----	--

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17610 (BOT)	SERIAL NO.: 10/685,986
APPLICANT: KATZ et al.	TITLE: BOTULINUM TOXIN DENTAL THERAPIES AND PROCEDURES
FILING DATE: October 14, 2003	GROUP:



CB	Armstrong M. et al. (1996) <i>Treatment of Facial Synkinesis and Facial Asymmetry with Botulinum Toxin Type A Following Nerve Palsy</i> , Clin. Otolaryngol. 21:15-20
CC	Bigalke H., et al., <i>Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture</i> , Brain Research 360;318-324:1985
CD	Bigalke H., et al., <i>Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord</i> , Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981
CE	Binz T. et al., <i>The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins</i> , J Biological Chemistry 265(16);9153-9158:1990
CF	Boutsen F., et al, <i>Botox treatment in adductor spasmodic dysphonia: A meta-analysis</i> , J Speech Lang Hear Res 2002;45(3):469-481
CG	Brandt F., et al., (1998) <i>Cosmetic Use of Botulinum A Exotoxin for the Aging Neck</i> , Dermatol. Surg. 24: 1232-1234
CH	Bushara K., <i>Botulinum toxin and rhinorrhea</i> , Otolaryngol Head Neck Surg 1996;114(3):507
CI	Carruthers J., et al (1996), <i>Botulinum A Exotoxin Use in Clinical Dermatology</i> ; J Amer Acad Derm 34: 788-797
CJ	Carruthers J., et al., (1996) <i>Botulinum A Exotoxin in Clinical Ophthalmology</i> ; Can. J. Ophthalmol. 31: 389-400
CK	Carruthers A., et al., <i>Cosmetic Uses of Botulinum A Exotoxin</i> ; in: James, W. D. et al Eds. <i>Advances in Dermatology</i> (1997) Mosby-Yearbook, Chicago
CL	Carruthers J., et al., (1992) <i>Treatment of Glabellar Frown Lines with C. Botulinum-A Exotoxin</i> ; J. Dermatol. Surg Oncol. 18: 17-21
CM	Duggan et al.; <i>A survey of Botulinum neurotoxin substrate expression in cells</i> ; Mov Disord, 10(3):376:1995
CN	Fross R., <i>Bruxism and masticatory myalgias: Use of botulinum toxin</i> , Mov Disord 2000;15(Suppl 2):35
CO	Gonelle-Gispert et al., <i>Snap-25a and -25b isoforms are both expressed in insulinsecreting cells and can function in insulin secretion</i> ; Biochem J 1;339 (pt 1):159-65:1999
CP	Habermann, E.; <i>I-Labeled Neurotoxin form Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord</i> ; Nauny-Schmiedeberg's Arch. Pharmacol. 1974; 281, 47-56


EXAMINER _____

DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17610 (BOT)	SERIAL NO.: 10/685,986
APPLICANT: KATZ et al.	TITLE: BOTULINUM TOXIN DENTAL THERAPIES AND PROCEDURES
FILING DATE: October 14, 2003	GROUP:




CQ	Habermann E., <i>Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate</i> , <i>Experientia</i> 44;224-226:1988
CR	Habermann E., et al., <i>Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain</i> , <i>J Neurochem</i> 51(2);522-527:1988)
CS	Jankovic J. et al., <i>Therapy With Botulinum Toxin</i> , Marcel Dekker, Inc., (1994), page 5.
CT	Jankovic J, ed. <i>Neurological Disease and Therapy. Therapy with botulinum toxin</i> New York: Marcel Dekker;1994;25:pp. 567-76
CU	Kemppainen et al.; Capsaicin stimulation of gingival induces local elevation in matrix metalloproteinase – 8 levels in gingival cervicular fluid in humans; Univ of Helsinki; Abstract (Society for Neuroscience)
CV	Maik, E., et al., <i>Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies</i> , <i>J Oral Maxillofac Surg</i> 2003 Apr;61(4):454-457
CW	Moyer E et al., <i>Botulinum Toxin Type B: Experimental and Clinical Experience</i> , being chapter 6, pages 71-85 of "Therapy With Botulinum Toxin", edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc.
CX	Naumann et al.; <i>Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions</i> ; <i>European J. Neurology</i> 6 (Supp 4): S111-S1150:1999
CY	Pearce, L.B., <i>Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine</i> , <i>Toxicon</i> 35(9);1373-1412 at 1393
CZ	Ragona et al.; <i>Management of Parotid Sialoceles With Botulinum Toxin</i> ; <i>The Laryngoscope</i> 109:1344-1346:1999
CAA	Sanchez-Prieto, J., et al., <i>Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes</i> , <i>Eur J. Biochem</i> 165;675-681:1897
CBB	Schantz, E.J., et al, <i>Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine</i> , <i>Microbiol Rev.</i> 56;80-99:1992
CCC	Schwartz M., et al., <i>Treatment of temporomandibular disorders with botulinum toxin</i> , <i>Clin J Pain</i> 2002;18(6 Suppl):S198-S203
CDD	Scott A., <i>Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery</i> , <i>Ophthalmology</i> 1980;87(10):1044-9
CEE	Singh, <i>Critical Aspects of Bacterial Protein Toxins</i> , pages 63-84 (chapter 4) of <i>Natural Toxins II</i> , edited by B.R. Singh et al., Plenum Press, New York (1976)

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF ART CITED BY APPLICANT

ATTY. DOCKET: 17610 (BOT)	SERIAL NO.: 10/685,986
APPLICANT: KATZ et al.	TITLE: BOTULINUM TOXIN DENTAL THERAPIES AND PROCEDURES
FILING DATE: October 14, 2003	GROUP:



	CFF	<i>Sloop et al.; Reconstituted Botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use; Neurology, 48:249-53:1997</i>
	CGG	Van Zandijcke M., et al., <i>Treatment of bruxism with botulinum toxin injections</i> , J Neurol Neurosurg Psychiatry 1990;53(6):530
	CHH	Weigand et al, I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after Intramuscular Injection; <i>Nauny-Schmiedeberg's Arch. Pharmacol.</i> 1976; 292, 161-165

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.